Serum Metabolomic and Lipoprotein Profiling of Pancreatic Ductal Adenocarcinoma Patients of African Ancestry

Simple item page
dc.article.start-page663en_ZA
dc.citation.doi10.3390/metabo11100663en_ZA
dc.contributor.authorElebo, Nnenna
dc.contributor.authorFru, Pascaline N.
dc.contributor.authorCandy, Geoffrey
dc.contributor.authorNweke, Ekene
dc.date.accessioned2021-11-16T12:27:50Z
dc.date.available2021-11-16T12:27:50Z
dc.date.issued2021
dc.departmentSurgery
dc.descriptionThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/)en_ZA
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a characteristic dysregulated metabolism. Abnormal clinicopathological features linked to defective metabolic and inflammatory response pathways can induce PDAC development and progression. In this study, we investigated the metabolites and lipoproteins profiles of PDAC patients of African ancestry. Nuclear Magnetic Resonance (NMR) spectroscopy was conducted on serum obtained from consenting individuals (34 PDAC, 6 Chronic Pancreatitis, and 6 healthy participants). Seventy-five signals were quantified from each NMR spectrum. The Liposcale test was used for lipoprotein characterization. Spearman’s correlation and Kapan Meier tests were conducted for correlation and survival analyses, respectively. In our patient cohort, the results demonstrated that levels of metabolites involved in the glycolytic pathway increased with the tumour stage. Raised ethanol and 3-hydroxybutyrate were independently correlated with a shorter patient survival time, irrespective of tumour stage. Furthermore, increased levels of bilirubin resulted in an abnormal lipoprotein profile in PDAC patients. Additionally, we observed that the levels of a panel of metabolites (such as glucose and lactate) and lipoproteins correlated with those of inflammatory markers. Taken together, the metabolic phenotype can help distinguish PDAC severity and be used to predict patient survival and inform treatment intervention.en_ZA
dc.description.librarianLTM2021en_ZA
dc.facultyFaculty of Health Sciencesen_ZA
dc.funderWits Open Access Publishing Funden_ZA
dc.identifier.citation.1. Elebo N., Omoshoro-Jones J., Fru P. N., et al. Serum Metabolomic and Lipoprotein Profiling of Pancreatic Ductal Adenocarcinoma Patients of African Ancestry. Metabolites. 2021;11(10):663. DOI: 10.3390/metabo11100663en_ZA
dc.identifier.urihttps://hdl.handle.net/10539/32002
dc.journal.issue10en_ZA
dc.journal.linkhttps://www.mdpi.com/2218-1989/11/10/663en_ZA
dc.journal.titleMetabolitesen_ZA
dc.journal.volume11en_ZA
dc.language.isoenen_ZA
dc.publisherMDPIen_ZA
dc.rightsCC Attribution 4.0en_ZA
dc.schoolSchool of Clinical Medicineen_ZA
dc.subjectPancreasen_ZA
dc.subjectAdenocarcinomaen_ZA
dc.subjectMagnetic Resonance Spectroscopyen_ZA
dc.subjectLipoproteinsen_ZA
dc.subjectpancreatic ductal adenocarcinomaen_ZA
dc.titleSerum Metabolomic and Lipoprotein Profiling of Pancreatic Ductal Adenocarcinoma Patients of African Ancestryen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Serum metabolomics and lipoprotein profiling of PDAC.pdf
Size:
2.35 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Outputs (Clinical Medicine)
Academic Wits Research Outputs (All submissions)